Chemokine C-X-C ligand 16 (CXCL16), a single-pass Type I membrane protein belonging to the CXC chemokine family, is related to the inflammatory response in liver injury. In present study, we investigated the pathophysiological role of CXCL16, a unique membrane-bound chemokine, in acetaminophen (APAP)-induced hepatotoxicity in mice. Mice were injected with APAP, and blood and tissue samples were harvested at different time points. The serum high-mobility group box 1 and CXCL16 levels were quantified by sandwich immunoassays. The liver tissue sections were stained with hematoxylin-eosin or with dihydroethidium staining. The expressions of CXCL16 and other cytokines were examined by real-time polymerase chain reaction. Ly6-B, p-jun N-terminal kinase (p-JNK), and JNK expressions were measured by western blot analysis. Intracellular glutathione, reactive oxygen species, and malondialdehyde levels were also measured. APAP overdose increased hepatic CXCL16 mRNA and serum CXCL16 protein levels. CXCL16-deficient mice exhibited significantly less liver injury and hepatic necrosis, as well as a lower mortality than wild-type (WT) mice in response to APAP-overdose treatment. APAP elevated the production of oxidative stress and decreased mitochondrial respiratory chain activation in WT mice, which was strongly reversed in CXCL16-knockout mice. In addition, CXCL16 deficiency inhibited the neutrophil infiltration and the production of proinflammatory cytokines triggered by APAP-overdose treatment. Our study revealed that CXCL16 is a critical regulator of liver immune response to APAP-induced hepatotoxicity, thus providing a potential strategy for the treatment of drug-induced acute liver failure by targeting CXCL16.
Introduction
Acetaminophen (APAP) is a widely used analgesic and antipyretic drug that is safe at therapeutic doses but can cause massive hepatocyte necrosis at high doses. APAP overdose is a very common drug overdose and the leading cause of acute liver injury (ALI) in the developed world [1] . Overdosed APAP is metabolized by hepatic cytochrome P450 2E1 (CYP2E1) into the reactive metabolite Nacetyl-p-benzoquinone imine (NAPQI), which depletes glutathione (GSH), a critical factor in maintaining redox balance [2] . A high dose of APAP can also enable the covalent binding of NAPQI to mitochondrial proteins and cause mitochondrial dysfunction, resulting in ATP depletion and intracellular oxidative stress [3, 4] . The depletion of ATP and redox imbalance have been implicated to induce the opening of the membrane permeability transition pore, DNA damage, and necrosis of hepatocytes [3] [4] [5] .
Chemokine C-X-C ligand 16 (CXCL16), also known as smallinducible cytokine B16 and SR-PSOX, is a single-pass Type I membrane protein belonging to the CXC chemokine family. CXCL16 is expressed on the surface of antigen-presenting cells, including macrophages, dendritic cells, monocytes, and subsets of CD19 B cells [6] [7] [8] . The expression of CXCL16 has been detected in the hepatocytes and bile ducts of patients with liver diseases, and CXCL16 affects the local inflammatory response in the liver [9] [10] [11] . In addition, the overexpression of CXCL16 has been shown to suppress migration and invasion as well as to induce apoptosis of breast cancer cells [12] . The generation of CXCL16 and its receptor CXCR6 always is accompanied by massive cell necrosis [12] . Moreover, neutrophil infiltration was observed in APAP-induced liver injury [13] . Previous studies also indicated that inflammation plays an important role in APAP-induced ALI [14] . This injury triggers a sterile inflammatory response with formation of cytokines and innate immune cell infiltration in the liver. And the APAP-induced release of necrotic products and chemokines aggravates the systemic inflammatory response and the progression of acute liver failure (ALF) [15] .
In the present study, we investigated the dynamic changes in the hepatic expression and serum level of CXCL16 in APAP-overdoseinduced ALI mice. We also examined the levels of oxidative stress, neutrophil activation, and proinflammatory cytokines in the liver tissues from wild-type (WT) and CXCL16-knockout (KO) mice with APAP treatment. The experimental evidence suggests a critical role of CXCL16 in mediating liver injury.
Materials and Methods

Animal studies
All animal experiments, protocols used for survival study, and mortality aspects were approved by the Wenzhou Medical University Animal Policy and Welfare Committee (Approved documents: wydw2013-0058) and complied with the NIH guideline (Guide for the Care and Use of Laboratory Animals). CXCL16-KO mice with a C57BL/6J genetic background were originally provided friendly by Prof. Jie Du from Capital Medical University affiliated Beijng Anzhen Hospital (Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China) [16] and further the CXCL16-KO mice with a background of C57BL/6J were generated according to previously described method [17] . Briefly, C57BL/6J mice were regularly crossed with CXCL16-KO mice of the same background, and CXCL16 heterozygous mice were further crossed to generate CXCL16-KO mice and WT littermates for our study. For all our experiments, littermates were used and co-housed with the KO mice. All mice were housed under specific pathogen-free conditions and studied at 8 weeks old. The fed mice were intraperitoneally injected with APAP dissolved in phosphate-buffered saline (PBS) (Sigma-Aldrich, St Louis, USA) at dose of 500 or 750 mg/kg to induce hepatotoxicity or with an equal volume of PBS as control [18] . Blood and tissue samples were harvested at different time points after treatment for biochemical, immunological, and histological analyses.
Considering that the use of pain relievers or anesthesia at the early stage of survival study may affect the final results, euthanasia only was used prior to the end of APAP-overdose treatment experiments. After APAP administration, if the animals appeared some abnormal symptoms, such as body weight changes, behavioral changes, external physical appearance, and physiological changes, they were moved to a clean and quiet place and comforted in order to minimize the suffering and distress. The mice that were still alive 36 h after APAP-overdose treatment would be euthanized in a CO 2 chamber.
Biochemical and immunological analyses of serum samples
Blood was collected from the WT and CXCL16-KO mice at 0, 4, 8, 12 , and 24 h after injection with APAP or PBS. Serum was then separated from the clotted blood by centrifugation at 200 g for 15 min at 4°C. The serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were measured using Diagnostics ALT and AST test kits from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). The serum CXCL16 level and high-mobility group box 1 (HMGB1) level were quantified using sandwich immunoassay kits from Sigma-Aldrich and ShinoTest Corporation (Tokyo, Japan), respectively.
Immunofluorescence staining and immunohistochemistry staining
The liver tissues collected at 0, 6, 12, and 24 h after injection with APAP or PBS were fixed in 10% formalin solution and then dehydrated through a series of graded ethanol solutions. The liver tissue sections were stained with hematoxylin-eosin (H&E) and immunohistochemistry staining for evaluating the change of hepatic morphology and neutrophil infiltration, respectively. For the detection of superoxide concentration, the liver sections were stained with dihydroethidium (DHE) (Sigma-Aldrich) as previously reported [19] . The stained liver tissues were examined under a BX51 microscope (Olympus, Kokyo, Japan), and the images were quantified using Image J software.
Measurement of CYP2E1 activities
The activity of CYP2E1 in liver microsome was estimated by colorimetrically measuring the formation of 4-nitrocatechol, a product from p-nitrophenol hydroxylation catalyzed specifically by CYP2E1. The protein concentration of CYP2E1 was measured using the ELISA kit (Calbiochem, Inc., San Diego, USA). The activity was expressed as the amount of 4-nitrocatechol formed per mg of CYP2E1 protein (nmol/mg proein).
Quantitative real-time polymerase chain reaction
Total RNA was extracted from the liver tissues using TRIzol reagent (Invitrogen, Carlsbad, USA) according to the manufacturer's instructions. cDNA was synthesized from 0.5 μg of RNA by reverse transcription using an ImProm-II reverse transcription kit (Takara, Dalian, China) with specially designed oligo dT primer. Quantitative real-time PCR was performed using SYBR Green (Invitrogen) on an iQ5 real-time PCR instrument (Bio-Rad, Hercules, USA) with specific mouse primers listed in Table 1 , mRNA expression was normalized to that of β-actin.
Immunoblot assay
The liver tissues were homogenized in lysis buffer (RIPA:PMSF:NaF = 100:1:5) and then centrifuged at 12,000 g for 15 min at 4°C. The supernatant was transferred to a fresh tube, and the protein concentration was measured by the Coomassie brilliant blue staning method. Equal amounts of liver lysates were resolved by 1.2% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidenedifluoride membranes. The membranes were blocked in a 10% skimmed milk solution and exposed to primary antibodies against Ly6-B, p-jun N-terminal kinase (p-JNK) or JNK, ICAM-1, and glyceraldehyde-3-phosphate dehydrogenase (Santa Cruz Biotechnology, Santa Cruz, USA) overnight at 4°C. The membranes were then incubated with the corresponding horseradish peroxidaseconjugated secondary antibodies (Santa Cruz Biotechnology). The blots were finally visualized with the enhanced chemiluminescence system (Santa Cruz Biotechnology). Representative data from three independent experiments are shown.
Measurements of intracellular GSH, reactive oxygen species, and malondialdehyde levels
Mouse livers were perfused with PBS to remove intravascular blood. Ten milligrams of liver tissue was homogenized in 1 ml of PBS containing 2 mM ethylene diaminetetraacetic acid. Fifty microliters of tissue extract was used to determine the GSH level with a GSH assay kit (Nanjing Jiancheng Bioengineering Institute) according to the manufacturer's instructions. Luminescence was detected at 405 nm with a Spectra Max M2 multimode microplate reader with Gen5 data analysis software (Bio-Rad). The malondialdehyde (MDA) concentrations in the liver tissues were determined using a commercial kit (Beyotimes, Nantong, China). The reactive oxygen species (ROS) levels in hepatic tissue were measured uisng an ROS assay kit (Nanjing Jiancheng Bioengineering Institute), which is based on carboxy-H 2 DCFDA, a reliable fluorogenic marker for ROS in hepatic tissues, and the fluorescence was measured at excitation and emission wavelengths of 488 and 525 nm, respectively [20] . The results are presented as the fold change of values in comparison with the control groups.
Statistical analysis
Data are expressed as the mean ± standard errors. Statistical calculations were performed with GraphPad Prism 5 (GraphPad Software, Inc., San Diego, USA). Statistical significance was determined by the Student's t-test (for comparison of two experimental conditions) or analysis of variance with ANOVA and by post hoc tests (for comparison of three or more experimental conditions). P values <0.05 were considered statistically significant.
Results
Effect of APAP overdose on CXCL16 expression in the liver
To determine whether CXCL16 participates in the pathogenesis of ALI induced by an APAP overdose, we first challenged C57BL/6J mice with APAP (500 mg/kg body weight) and measured the expression level of CXCL16 mRNA in the lung, heart, liver, kidney, and pancreas. As shown in Fig. 1A , 24 h after the APAP injection, the CXCL16 mRNA expression was significantly upregulated in the lung, heart, and liver. In contrast, CXCL16 expression in the kidney and pancreas was not affected by the APAP-overdose treatment. The induction of CXCL16 in the liver occurred in a time-dependent manner (Fig. 1B, 6 , 12, and 24 h). In addition, consistent with the expression of CXCL16 mRNA, serum CXCL16 exhibited significantly higher levels at 12 and 24 h compared to the baseline at 0 h (Fig. 1C) . These results suggest that CXCL16 may be involved in the pathogenesis of APAP-overdose-induced hepatotoxicity.
CXCL16-deficient mice exhibited attenuated APAP-induced liver injury
As the APAP-overdose treatment increased liver CXCL16 expression, we next examined whether CXCL16 deficiency affects APAPinduced ALI. As shown in Fig. 2A ,B, the APAP-overdose treatment markedly elevated the serum levels of ALT and AST, two biomarkers of liver injury, in WT mice. This induction of ALT and AST was significantly reduced in the CXCL16-deficient mice ( Fig. 2A,B) . Furthermore, we challenged mice with a lethal dose of APAP (750 mg/kg) and examined the mortality rates. As shown in Fig. 2C , CXCL16-deficient mice exhibited a better survival rate after treatment with a lethal dose of APAP compared to WT mice (58.3% vs. 27.7%, P < 0.05), indicating a protective role of CXCL16 deficiency in APAP-induced hepatotoxicity and mortality.
CXCL16 deficiency attenuated APAP-induced hepatocyte necrosis
Necrosis is the principal type of liver cell death in APAP-induced hepatotoxicity [21] . To examine whether CXCL16 deficiency affects APAP-overdose-induced hepatocyte necrosis, we investigated liver injury by histological evaluation and immunoassays. Figure 3A shows that CXCL16-KO mice exhibited less typical bridging necrosis within centrilobular region as compared to WT mice 24 h after injection with APAP (500 mg/kg). Additionally, the serum circulating concentrations of HMGB1, a marker of necrosis [22] , was significantly lower in CXCL16-KO mice as compared to WT mice (Fig. 3B) . These results suggest that CXCL16 deficiency can prevent APAP-overdose-induced hepatotoxicity by reducing hepatic necrosis.
CXCL16 deficiency decreased APAP-induced oxidative stress in the liver
An overdose of APAP is known to induce oxidative damage in mice, thus contributing to liver injury. In this study, we measured the hepatic GSH, ROS, and MDA levels in CXCL16-KO mice and WT mice after APAP treatment. Our data showed that hepatic GSH was almost depleted within 1 h after a high-dose APAP injection, and recovered within 24 h after APAP administration; meanwhile, no significant difference in the hepatic GSH concentration was observed between CXCL16-KO mice and WT mice (Fig. 4A) . This suggested that CXCL16-CXCR6 signaling may not affect APAP metabolism. In contrast, the accumulation of hepatic ROS and concentration of MDA, which is a lipid peroxidation product, as well as the activity of mitochondrial respiratory chain (MRC) were significantly reversed in CXCL16-KO mice as compared with WT mice (Fig. 4B-E) . However, no significant differences in the hepatic expression of CYP2E1 and NAPQI production were observed between CXCL16-KO mice and WT mice, suggesting that CXCL16 deficiency does not affect APAP metabolism in vivo (Fig. 4F) .
CXCL16-KO ameliorated neutrophil infiltration and decreased local hepatic inflammation in APAP-treated mice
Hepatic infiltration of neutrophils is an acute response to liver injury, hepatic stress, or unknown systemic inflammatory signals that consequently causes mild-to-severe tissue damage. Neutrophil-mediated liver injury has been demonstrated in a variety of diseases and chemical/drug toxicities [13, 23] . Therefore, we examined the differences of hepatic neutrophil infiltration between CXCL16-KO mice and WT mice at 12 h after APAP administration. Noticeably, the amounts of Ly6-B (a specific biomarker of neutrophils) accumulated in hepatic necrosis areas were significantly increased in both CXCL16-KO mice and WT mice after APAP administration, suggesting that APAP administration triggers the migration of neutrophils to the injured areas of hepatic tissues. Interestingly, the amounts of Ly6-B in hepatic areas were decreased by 67.2% in CXCL16-KO mice as compared with that of WT mice (Fig. 5A,B) , suggesting that APAP treatment causes neutrophil infltration to the damaged hepatic tissue, but the exact role of neutrophil infiltration requires further investigation. Furthermore, CXCL16 deficiency significantly reduced the migration of neutrophils to the injured hepatic tissues. Previous studies have demonstrated that neutrophil infiltration is related to the activation of several chemokines including CXCL1 and CXCL2. So we next examined the hepatic expressions of these chemokines in APAP-treated mice. Our data indicated that hepatic mRNA levels of CXCL1 and CXCL2 were significantly increased in both CXCL16-KO mice and WT mice after treatment with APAP; however, the extents of increase in CXCL1 and CXCL2 in CXCL16-KO mice were obviously lower than those in WT mice (Fig. 5C,D) . In addition, APAP overdose also induced an increased expression of ICAM-1, another adhesion molecule, in WT mice (Fig. 5E,F) , and this increased expression was not observed in CXCL16-KO mice, suggesting that CXCL16 deficiency obviously inhibited APAP-induced hepatic expression of chemokine, which may be involved in the migration of neutrophils to hepatic tissues.
CXCL16-KO mice showed reduced expression of inflammatory cytokines in the injured liver after APAP-overdose treatment
Previous studies have demonstrated that JNK signal is activated and involved in hepatic inflammation response in mice after over-dosage APAP exposures in mice [1] . Furthermore, chemokines are also involved in hepatic inflammation under oxidative stress status, which perpetuates hepatocyte necrosis and leads to liver injury [24, 25] . To further determine the roles of CXCL16 in APAPinduced neutrophil infiltration and hepatotoxicity, we next examined the phosphorylation levels of JNK and evaluated the differences of inflammatory factors in the liver tissue between CXCL16-KO mice and WT mice after APAP administration. Consistent with previous reports, APAP treatment significantly activated JNK phosphorylation in the livers of CXCL16-KO and WT mice. However, the extent of increase in JNK phosphorylation in CXCL16-KO mice was significantly attenuated as compared to that in WT mice (Fig. 6A) . Additionally, hepatic TNF-α and IL-6 in the early and later stages of APAP treatment were also significantly elevated in WT mice after APAP treatment, and this induction was inhibited by CXCL16 deficiency (Fig. 6B,C) .
Discussion
APAP overdose is the predominant cause of ALI, whereas the therapeutic options for its hepatotoxicity remain limited [1] . In the present study, we demonstrated that APAP-overdose induced CXCL16 expression in the mouse liver. CXCL16 deficiency significantly decreased APAP-induced liver injuries accompanied with lower ALT and AST levels, less hepatic necrosis and reduced mortality in mice when treated with APAP overdose. Our results suggest that the inhibition of CXCL16 may be a potential therapeutic option to alleviate APAP-induced ALF.
In APAP-overdose-induced liver injury, it has been shown that the mitochondria are a critical target for drug toxicity, either directly or indirectly through the formation of reactive metabolites. Overdosed APAP can be metabolized by hepatic CYP2E1 into reactive NAPQI, which leads to the depletion of GSH, a critical factor in maintaining redox balance [2] . Interestingly, the CXCL16-KO mice exhibited no significant difference in the reduction of GSH level in vivo compared with the WT mice in this study, suggesting that CXCL16 may not be involved in APAP metabolism. Hepatic oxidative stress induced by the binding of the APAP metabolite NAPQI to mitochondrial proteins is a central mediator of APAP-induced ALI [26] . JNK is a stress-activated protein kinase and plays an important role in ROS-induced cell death [27] , it has been reported that treatment with either antioxidants or pharmacological inhibitors of JNK can alleviate APAP-induced liver injury in animals [5, 28] . In this study, increased hepatic ROS and MDA levels triggered by APAP overdose were markedly attenuated in the CXCL16-KO mice. Additionally, APAP-induced JNK activation in the liver tissues was obviously blocked by CXCL16 deficiency [29] . Our findings demonstrated that the rescue of liver injury by CXCL16-KO in mice is at least partially attributed to its ability to attenuate hepatic oxidative stress and lower liver injury.
CXCL16 is a novel chemokine that interacts with only one receptor CXCR6, primarily mediates lymphocyte migration, and has been implicated in liver disease [10] . The soluble form of CXCL16 has been shown to trigger immunocytechemotaxis and lymphocyte recruitment; while in its transmembrane form, CXCL16 mediates cell-cell adhesion [7, 8, 30] . CXCR6 expression on the surface of neutrophils has been reported in several studies. CXCL16 is an additional neutrophil chemoattractant in cerebrospinal fluid in early pneumococcal meningitis, which may be due to the upregulation of CXCL16 receptor CXCR6 in neutrophils [31] . Furthermore, CXCR6 expressed on polymorphonuclear neutrophils in pancreatic carcinoma and in acute, localized bacterial infections, which will be stimulated by TNF-α [32] . The CD8 + cells and CD56 + cells (hepatocyte enriched) in the liver commonly express CXCR6 [10] . A recent report has shown that the whole-liver expression of CXCL16 is increased in fatty liver disease with increasing steatohepatitis and fibrosis, compared with the normal liver [33] . And the inhibition of CXCR6 or CXCL16 impedes the transmigration of lymphocytes across hepatic sinusoidal endothelial cells [33] . In the present study, we found that treatment of mice with APAP significantly induced the upregulation of hepatic CXCL16 expression following with serious local and systemic inflammatory response. Therefore, we speculate that the upregulation of CXCL16 in APAP-induced liver injury may be related to the local and systemic inflammatory response. In support of this notion, CXCL16 expression was significantly increased under inflammation condition [7, 8] .
Consistent with previous studies [13] , neutrophil infiltration was also observed in the lesion position of injured liver tissues. Furthermore, CXCL16 deficiency significantly decreased neutrophil infiltration in the liver of APAP-treated mice, following with the attenuated expression of molecules critical to cell-cell adhesion (e.g. ICAM-1) and other relevant chemokines including CXCL1 and CXCL2 in the livers of CXCL16-KO mice as compared with WT mice, suggesting that CXCL16 may be involved in neutrophil infiltration in APAP-induced liver injury. CXCL1 and CXCL2 are previously considered as potential stimulators of neutrophil infiltration [34] , so we speculate that CXCL1 and CXCL2 may be involved in CXCL16-mediated neutrophil infiltration in APAP-induced liver injury, but the exact role of neutrophil infiltration in APAP-induced liver injury required to be further investigated.
Hepatic inflammation is common in a variety of liver diseases, including drug-induced liver toxicity. The infiltration of neutrophils to the liver is known to confer the liver inflammatory response [35, 36] . It has been reported that after sterile cell death, neutrophils emigrate to sites of necrosis where they participate in the healing process and the removal of cell debris [37] . However, inappropriate neutrophil infiltration contributes to the pathogenesis and intensification of several diseases, including gout [38] , arthritis [39] , and acute hepatocyte necrosis [15] . Xia et al. [40] reported that CXCL16 deficiency can reduce the expressions of angiotensin II-induced inflammatory cytokines in mouse kidney. In agreement with the previous study, our results showed that the expressions of two inflammatory cytokines, TNF-α and IL-6 were reduced in CXCL16-KO mice. As we know, both oxidative stress and inflammation are the causative factors of DNA damage. Hence, these findings provide further evidence for our earlier data that CXCL16-deficient mice have less accumulation of ROS and lower MDA (a lipid peroxidation product) level in the liver compared with WT mice.
CXCL16, a member of chemokine family, plays an important role in the regulation of inflammatory response in the pathogenesis of several types of diseases. Numerous studies have demonstrated that CXCL16 not only involves in inflammatory response but also regulates the migration of neutrophils and macrophages, then further accelerates the release of the inflammatory mediators, and amplifies local and systemic inflammatory response [10, 41, 42] . In present study, our data indicate that liver injuries in both early and late phases are attenuated in CXCL16-KO mice, accompanied with decreasing neutrophil accumulation, chemokine formation, ICAM-1 expression, and so on. Therefore, we speculate that the attenuation of APAP-induced liver injury by CXCL16 deficiency may be at least in part mediated by the inhibition of inflammatory response, but how CXCL16 participates in the APAP-activated inflammatory response is still unclear. Further studies should focus on distinguishing between cause and effect on this topic.
As there is no CXCL16 null-type model in human body, whether CXCL16 deficiency is beneficial for APAP-induced liver injury in human still remains unclear. In present study, we just focus on the mouse experiments and hope to provide some useful information that can be used in relevant human research. In the future, we will focus on the development of novel diagnostic biomarkers and new drugs.
In summary, we demonstrate that CXCL16 deficiency attenuates APAP-induced liver injury through activating relevant chemokines including CXCL1 and CXCL2, as well as JNK activation, and then promoting neutrophil infiltration and inflammatory response, and finally leading to the block of liver injury. However, the exact mechanism through which CXCL16 deficiency protects against APAPinduced liver injury still requires to be further explored. Our study implicates that inhibition of CXCL16 may represent a new strategy for the treatment of liver disease and drug-induced liver injury. D) and IL-6 (C, E) in the liver tissues at 4 and 24 h of APAP treatment were examined by quantitative RT-PCR respectively. Data are expressed as the mean ± standard errors. n = 6. *P < 0.05, **P < 0.01.
